Cardiovascular autonomic dysfunction in animal models of parkinson's disease

Journal of Parkinson's Disease

Volumn 1, Issue 4, 2011, Pages 321-327

  Fleming, Sheila M ^a  

^a UNIVERSITY OF CINCINNATI   (United States)

Author keywords

6 hydroxydopamine; Alpha synuclein; baroreflex; heart rate variability; MPTP; orthostatic hypotension; sympathetic denervation

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ALPHA SYNUCLEIN; OXIDOPAMINE;

ADRENERGIC ACTIVITY; ALPHA SYNUCLEIN GENE; AUTONOMIC DENERVATION; AUTONOMIC DYSFUNCTION; BLOOD PRESSURE REGULATION; CENTRAL NERVOUS SYSTEM DISEASE; CHOLINERGIC ACTIVITY; DIFFUSE LEWY BODY DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; DOPAMINE RELEASE; EXPERIMENTAL MODEL; GENE; GENE MUTATION; GENE REPLICATION; GENETIC MODEL; HEART DISEASE; HEART RATE VARIABILITY; HUMAN; MOLECULAR PATHOLOGY; NONHUMAN; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PERIPHERAL NEUROPATHY; PRESSORECEPTOR REFLEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SHY DRAGER SYNDROME; SYMPTOMATOLOGY;

ALPHA-SYNUCLEIN; ANIMALS; AUTONOMIC NERVOUS SYSTEM DISEASES; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; DISEASE MODELS, ANIMAL; HEART RATE; HUMANS; PARKINSON DISEASE;

EID: 84858243373     PISSN: 18777171     EISSN: 1877718X     Source Type: Journal    
DOI: 10.3233/JPD-2011-11042     Document Type: Review

References (77)

1. Trojanowski JQ, & Lee VM (2003) Parkinson's disease and related alpha-synucleinopathies arebrain amyloidoses. Ann N Y Acad Sci, 991, 107-110.
2. Amino T, Orimo S, Itoh Y, Takahashi A, Uchihara T,&Mizusawa H (2005) Profound cardiac sympathetic denervation occurs in Parkinson disease. Brain Pathol, 15, 29-34.
3. Goldstein DS, Holmes CS, Dendi R, Bruce SR, Li ST (2002) Orthostatic hypotension from sympathetic denervation in Parkinson's disease. Neurology, 58, 1247-1255.
4. Orimo S, Oka T, Miura H, Tsuchiya K, Mori F,Wakabayashi K, Nagao T, & YokochiM(2002) Sympathetic cardiac denervation in Parkinson's disease and pure autonomic failure but not in multiple system atrophy. J Neurol Neurosurg Psychiatry, 73, 776-777.
5. Goldstein DS, Eldadah BA, Holmes C, Pechnik S, Moak J, Saleem A, & Sharabi Y (2005) Neurocirculatory abnormalities in Parkinson disease with orthostatic hypotension: Independence from levodopa treatment. Hypertension, 46, 1333-1339.
6. Schmidt C, Herting B, Prieur S, Junghanns S, Schweitzer K, Globas C, Schöls L, Reichmann H, Berg D, & Ziemssen T (2009) Valsalva manoeuvre in patients with different Parkinsonian disorders. J Neural Transm, 116, 875-880.
7. Plaschke M, Trenkwalder P, Dahlheim H, Lechner C, & Trenkwalder C (1998) Twenty-four-hour blood pressure profile and blood pressure responses to head-up tilt tests in Parkinson's disease and multiple system atrophy. J Hypertens, 16, 1433-1441.
8. Biaggioni I (2007) Parkinson's disease: Autonomic neuronopathy with impaired cardiovascular regulation. Hypertension, 49, 21-22.
9. Buob A, Winter H, Kindermann M, Becker G, Möller JC, Oertel WH, & BöhmM(2010) Parasympathetic but not sympathetic cardiac dysfunction at early stages of Parkinson's disease. Clin Res Cardiol, 9, 701-706.
10. Rahman F, Pechnik S, Gross D, Sewell L, & Goldstein DS (2011) Low frequency power of heart ratevariability reflects baroreflex function, not cardiac sympathetic innervation. Clin Auton Res, 21, 133-141.
11. Valappil RA, Black JE, Broderick MJ, Carrillo O, Frenette E, Sullivan SS, Goldman SM, Tanner CM, & Langston JW (2010) Exploring the electrocardiogram as a potential tool to screen for premotor Parkinson's disease. Mov Disord 25 2296-2303.
12. Barbic F, Perego F, Canesi M, Gianni M, Biagiotti S, Costantino G, Pezzoli G, Porta A, Malliani A, & Furlan R (2007) Early abnormalities of vascular and cardiac autonomic control in Parkinson's disease without orthostatic hypotension. Hypertension, 49, 120-126.
13. Kaufmann H, Nahm K, Purohit D, & Wolfe D (2004) Autonomic failure as the initial presentation of Parkinson disease and dementia with Lewy bodies. Neurology, 63, 1093-1095.
14. Minguez-Castellanos A, Chamorro CE, Escamilla-Sevilla F, Ortega-Moreno A, Rebollo AC, Gomez-Rio M, Concha A, & Munoz DG (2007) Do alpha-synuclein aggregates in autonomic plexuses predate Lewy body disorders?: A cohort study. Neurology, 68, 2012-2018.
15. Goldstein DS, SharabiY, Karp BI, Bentho O, Saleem A, Pacak K, & Eisenhofer G (2009) Cardiac sympathetic denervation preceding motor signs in Parkinson disease. Cleve Clin J Med, Suppl 2, S47-50.
16. Goldstein DS (2006) Orthostatic hypotension as an early finding in Parkinson's disease. Clin Auton Res, 16, 46-54.
17. Orimo S, Takahashi A, Uchihara T, Mori F, Kakita A, Wakabayashi K, & Takahashi H (2007) Degeneration of cardiac sympathetic nerve begins in the early disease process of Parkinson's disease. Brain Pathol, 17, 24-30.
18. Fujishiro H, Frigerio R, Burnett M, Klos KJ, Josephs KA, Delledonne A, Parisi JE, Ahlskog JE, & Dickson DW(2008) Cardiac sympathetic denervation correlates with clinical and pathologic stages of Parkinson's disease. Mov Disord, 23, 1085-1092.
19. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, & Braak E (2003) Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging, 24, 197-211.
20. Iijima M, Osawa M, Momose M, Kobayakawa T, Saito S, Iwata M,&Uchiyama S (2010) Cardiac sympathetic degeneration correlates with olfactory function in Parkinson's disease. Mov Disord, 25, 1143-1149.
21. Kim JS, Shim YS, Song IU, Yoo JY, Kim HT, Kim YI, & KS Lee (2009) Cardiac sympathetic denervation and its association with cognitive deficits in Parkinson's disease. Parkinsonism Relat Disord, 15, 706-708.
22. Peralta C, Stampfer-Kountchev M, Karner E, Köllensperger M, Geser F,Wolf E, Seppi K, Benke T, PoeweW, &Wenning GK (2007) Orthostatic hypotension and attention in Parkinson's disease with and without dementia. J Neural Transm, 114, 585-588.
23. Postuma RB, Lanfranchi PA, Blais H, & Gagnon JF, Montplaisir JY (2010) Cardiac autonomic dysfunction in idiopathic REM sleep behavior disorder. Mov Disord, 25, 2304-2310.
24. Forno LS, & Norville RL (1976) Ultrastructure of Lewy bodies in the stellate ganglion. Acta Neuropathol (Berl), 34, 183-197.
25. Rajput AH, & Rozdilsky B (1976) Dysautonomia in Parkinsonism: A clinicopathological study. J Neurol Neurosurg Psychiatry, 39, 1092-1100.
26. Iwanaga K, Wakabayashi K, Yoshimoto M, Tomita I, Satoh H, Takashima H, Satoh A, Seto M, Tsujihata M, & Takahashi H (1999) Lewy body-type degeneration in cardiac plexus in Parkinson's and incidental Lewy body diseases. Neurology, 52, 1269-1271.
27. GaiWP, Geffen LB, Denoroy L,&BlessingWW(1993) Loss of C1 and C3 epinephrine-synthesizing neurons in the medulla oblongata in Parkinson's disease. Ann Neurol, 33, 357-367.
28. Singleton A, Gwinn-Hardy K, Sharabi Y, Li ST, Holmes C, Dendi R, Hardy J, Singleton A, Crawley A, & Goldstein DS (2004) Association between cardiac denervation and parkinsonism caused by alpha-synuclein gene triplication. Brain, 127, 768-772.
29. Orimo S, Uchihara T, Nakamura A, Mori F, Ikeuchi T, Onodera O, Nishizawa M, Ishikawa A, Kakita A, Wakabayashi K, & Takahashi H (2008a) Cardiac sympathetic denervation in Parkinson's disease linked to SNCA duplication. Acta Neuropathol, 116, 575-577.
30. Orimo S, Uchihara T, Nakamura A, Mori F, Kakita A, Wakabayashi K, & Takahashi H (2008b) Axonal alpha-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson's disease. Brain, 131, 642-650.
31. Orimo S, Uchihara T, Kanazawa T, Itoh Y, Wakabayashi K, Kakita A, & Takahashi H (2011) Unmyelinated axons are more vulnerable to degeneration than myelinated axons of the cardiac nerve in Parkinson's disease. Neuropathol Appl Neurobiol, 37, 791-802.
32. Ungerstedt U (1968) 6-Hydroxy-dopamine induced degeneration of central monoamine neurons. European Journal of Pharmacology, 5, 107-110.
33. Ungerstedt U (1971) Adipsia and aphagia after 6-hydroxydopamine induced degeneration of the nigro-striatal dopamine system. Act Physiol Scand Suppl, 367, 95-122.
34. Kostrzewa RM, & Jacobwitz DM (1974) Pharmacological actionsof 6-hydroxydopamine. Pharmacological Review, 26, 199-288.
35. Schallert T, Wilcox RE (1985) Neurotransmitter-selective brain lesions. In Neuromethods (Series 1: Neurochemistry), General Neurochemical Techniques (Boulton A. A. and Baker G. B., Eds.), Humana Press, Totowa, NJ. 343-387.
36. Kirik D, Rosenblad C, & Bjorklund A (1998) Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat. Experimental Neurology, 152, 259-277.
37. Lu SF, Young HJ, & Lin MT (1995) Nigrostriatal dopamine system mediates baroreflex sensitivity in rats. Neurosci Lett, 190, 17-20.
38. KriegerEM(1967) Effect of sinoaortic denervation on cardiac output. Am J Physiol, 213, 139-142.
39. Alexander N, Hirata Y,&Nagatsu T (1984) Reduced tyrosine hydroxylase activity in nigrostriatal system of sinoaorticdenervated rats. Brain Res, 299, 380-382.
40. Alexander N, Nakahara D, Ozaki N, Kaneda N, Sasaoka T, Iwata N, & Nagatsu T (1988) Striatal dopamine release and metabolism in sinoaortic-denervated rats by in vivo microdialysis. Am J Physiol, 254, R396-R399.
41. Yu JG,Wu J, Shen FM, Cai GJ, Liu JG,&Su DF (2008) Arterial baroreflex dysfunction fails to mimic Parkinson's disease in rats. J Pharmacol Sci, 108, 56-62.
42. Sei H, Ikemoto K, Arai R, & Morita Y (1999) Injection of 6-hydroxydopamine into the ventral tegmental area suppresses the increase in arterial pressure during REM sleep in the rat. Sleep Res Online, 2, 1-6.
43. Sakata M, Sei H, Toida K, Fujihara H, Urushihara R, & MoritaY(2002) Mesolimbic dopaminergic system is involved in diurnal blood pressure regulation. Brain Res, 928, 194-201.
44. Slack K, Billing R, Matthews S, Allbutt HN, Einstein R, & Henderson JM (2010) Subtle cardiovascular dysfunction in the unilateral 6-hydroxydopamine-lesioned rat. Parkinsons Dis, 2010, 1-10.
45. Fuller RW, Hahn RA, Snoddy HD, & Wikel JH (1984) Depletion of cardiac norepinephrine in rats and mice by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Biochem Pharmaco, l33, 2957-2960.
46. Fukumitsu N, Suzuki M, Fukuda T, Kiyono Y, Kajiyama S, & Saji H (2006) Reduced 125I-meta-iodobenzylguanidine uptake and norepinephrine transporter density in the hearts of mice with MPTP-induced parkinsonism. Nucl Med Biol, 33, 37-42.
47. Fukumitsu N, Suzuki M, Fukuda T, & Kiyono Y (2009) Multipoint analysis of reduced (125)I-meta-iodobenzylguanidine uptake and norepinephrine turnover in the hearts of mice with 1-methyl-4-phenyl-1,2,3,6- tetrahydroxypyridineinduced parkinsonism. Nucl Med Biol, 36, 623-629.
48. Takatsu H, Nishida H, Matsuo H,Watanabe S, Nagashima K, Wada H, Noda T, Nishigaki K, & Fujiwara H (2000) Cardiac sympathetic denervation from the early stage of Parkinson's disease: Clinical and experimental studies with radiolabeled MIBG. J Nucl Med, 41, 71-77.
49. Ren J, Porter JE, Wold LE, Aberle NS, Muralikrishnan D, & Haselton JR (2004) Depressed contractile function and adrenergic responsiveness of cardiac myocytes in an experimental model of Parkinson disease, the MPTP-treated mouse. Neurobiol Aging, 25, 131-138.
50. Amino T, Uchihara T, Tsunekawa H, Takahata K, Shimazu S, Mizusawa H, & Orimo S (2008) Myocardial nerve fibers are preserved in MPTP-treated mice, despite cardiac sympathetic dysfunction. Neurosci Res, 60, 314-318.
51. Goldstein DS, Li ST, Holmes C, & Bankiewicz K (2003) Sympathetic innervation in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine primate model of Parkinson's disease. J Pharmacol Exp The, 306, 855-860.
52. Singleton A, Gwinn-Hardy K, Sharabi Y, Li ST, Holmes C, Dendi R, Hardy J, Singleton A, Crawley A, & Goldstein DS (2004) Association between cardiac denervation and parkinsonism caused by alpha-synuclein gene triplication. Brain, 127, 768-772.
53. Goldstein DS, Imrich R, Peckham E, Holmes C, Lopez G, Crews C, Hardy J, Singleton A,&HallettM(2007) Neurocirculatory and nigrostriatal abnormalities in Parkinson disease from LRRK2 mutation. Neurology, 69, 1580-1584.
54. Tijero B, Gomez-Esteban JC, Llorens V, Lezcano E, Gonzalez- Fernández MC, de Pancorbo MM, Ruiz-Martinez J, Cembellin JC, & Zarranz JJ (2010) Cardiac sympathetic denervation precedes nigrostriatal loss in the E46K mutation of the alpha-synuclein gene (SNCA). Clin Auton Res, 20, 267-269.
55. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe LI, & Nussbaum RL (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science, 276, 2045-2047.
56. Kruger R,KuhnW, Muller T,Woitalla D, Graeber M,Kosel S, Przuntek H, Epplen JT, Schols L, & Riess O (1998) Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet, 18, 106-108.
57. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, Hulihan M, Peuralinna T, Dutra A, Nussbaum R, Lincoln S, Crawley A, Hanson M, Maraganore D, Adler C, Cookson MR, Muenter M, Baptista M, Miller D, Blancato J, Hardy J, & Gwinn-Hardy K (2003) alpha-Synuclein locus triplication causes Parkinson's disease. Science, 302, 841.
58. Chartier-Harlin MC, Kachergus J, Roumier C, Mouroux V, Douay X, Lincoln S, Levecque C, Larvor L, Andrieux J, Hulihan M, Waucquier N, Defebvre L, Amouyel P, Farrer M, & DesteeA(2004) Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet, 364, 1167-1169.
59. SpillantiniMG,Schmidt ML, LeeVM,Trojanowski JQ, Jakes R, & Goedert M (1997) Alpha-synuclein in Lewy bodies. Nature, 388, 839-840.
60. Lotharius J, & Brundin P (2002) Pathogenesis of Parkinson's disease: Dopamine, vesicles and alpha-synuclein. Nat Rev Neurosci, 3, 932-942.
61. Nemani VM, Lu W, Berge V, Nakamura K, Onoa B, Lee MK, Chaudhry FA, Nicoll RA, & Edwards RH (2010) Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron, 65, 66-79.
62. Marrachelli VG, Miranda FJ, Alabadí JA, Milán M, Cano-Jaimez M, Kirstein M, Alborch E, Fariñas I,&Pérez- Sánchez F (2010) Perivascular nerve fiber-synuclein regulates contractility of mouse aorta: A link to autonomic dysfunction in Parkinson's disease. Neurochem Int, 56, 991-998.
63. Wang L, Fleming SM, Chesselet M-F, & Taché Y (2008) Abnormal colonic motility in mice overexpressing human wildtype alpha-synuclein. NeuroReport, 19, 873-876.
64. George S, van den Buuse M, San Mok S, Masters CL, Li QX, & Culvenor JG (2008) Alpha-synuclein transgenic mice exhibit reduced anxiety-like behaviour. Exp Neurol, 210, 788-792.
65. Graham DR, & Sidhu A (2010) Mice expressing the A53T mutant form of human alpha-synuclein exhibit hyperactivity and reduced anxiety-like behavior. J Neurosci Res, 88, 1777-1783.
66. Nuber S, Petrasch-Parwez E, Winner B, Winkler J, von Hörsten S, Schmidt T, Boy J, Kuhn M, Nguyen HP, Teismann P, Schulz JB, Neumann M, Pichler BJ, Reischl G, Holzmann C, Schmitt I, Bornemann A, Kuhn W, Zimmermann F, Servadio A, & Riess O (2008) Neurodegeneration and motor dysfunction in a conditional model of Parkinson's disease. J Neurosci, 28, 2471-2484.
67. Kuo YM, Li Z, Jiao Y, Gaborit N, Pani AK, Orrison BM, Bruneau BG, Giasson BI, Smeyne RJ, Gershon MD, & Nussbaum RL (2010) Extensive enteric nervous system abnormalities in mice transgenic for artificial chromosomes containing Parkinson disease-associated alpha-synuclein gene mutations precede central nervous system changes. Hum Mol Genet, 19, 1633-1650.
68. Rockenstein E, Mallory M, Hashimoto M, Song D, Shults CW, Lang I, Masliah, E (2002) Differential neuropathological alterations in transgenic mice expressing alpha-synuclein from the platelet-derived growth factor and Thy-1 promoters. J Neurosci Res, 68, 568-578.
69. Fernagut PO, Hutson CB, Fleming SM, Tetreaut NA, Salcedo J, Masliah E, & Chesselet MF (2007) Behavioral and histopathological consequences of paraquat intoxication in mice: Effects of alpha-synuclein over-expression. Synapse, 61, 991-1001.
70. Fleming SM, Tetreault NA, Mulligan CK, Hutson CB, Masliah E, & Chesselet MF (2008) Olfactory dysfunction in mice overexpressing human wildtype alpha-synuclein. Eur J Neurosci, 28, 247-256.
71. Fleming SM, Salcedo J, Fernagut PO, Rockenstein E, Masliah E, Levine MS, & Chesselet MF (2004) Early and progressive sensorimotor anomalies in mice overexpressing wild-type human alpha-synuclein. J Neurosci, 24, 9434-9440.
72. Fleming SM, Jentsch JD, & Chesselet M-F (2011) Cognitive Dysfunction in Genetic Mouse Models of Parkinsonism. In Van Dam D (ed.), Animal Models of Dementia, Neuromethods, Springer: Humana Press, 48, pp. 485-492.
73. Mulligan CK, Fleming SM, Dorriz P, Masliah E, & Chesselet M-F (2008) Mice overexpressing human wildtype alpha-synuclein under the Thy-1 promoter exhibit anomalies in behavioral tests of anxiety. Program No. 742.19 2008 Neuroscience Meeting Planner. Society for Neuroscience, Washington, DC.
74. Lam HA,Wu N, Cely I, Kelly RL, Hean S, Richter F, Magen I, Cepeda C, Ackerson LC, Walwyn W, Masliah E, Chesselet MF, Levine MS, & Maidment NT (2011) Elevated tonic extracellular dopamine concentration and altered dopamine modulation of synaptic activity precede dopamine loss in the striatum of mice overexpressing human-synuclein. J Neurosci Res, 89, 1091-102.
75. Fleming SM, Jordan MC, Masliah E, Chesselet M-F, & Roos KP (2007) Alterations in baroreceptor function in transgenic mice overexpressing human wildtype alpha synuclein. Program No. 50.9. Neuroscience Meeting Planner. Society for Neuroscience, San Diego, CA.
76. Fleming SM, Holden JG, Sioshansi PC, Jordan MC, Masliah E, & Roos KP (2009) Alterations in heart rate variability in transgenic mice overexpressing human wildtype alpha synuclein. Program No. 531.9 Neuroscience Meeting Planner. Society for Neuroscience, Chicago, IL.
77. Idiaquez J, Benarroch EE, Rosales H, Milla P,&RíosL(2007) Autonomic and cognitive dysfunction in Parkinson's disease. Clin Auton Res, 17, 93-98.